Asthma Drug May Lead to New Treatments for Diabetes and Obesity


The obese mouse on the right was fed a high-fat diet. The mouse on the left was fed the same diet but is a normal weight after receiving amlexanox. Image credit: Shannon Reilly.

A newly published study from the University of Michigan found that a currently available asthma drug reverses obesity, diabetes and fatty liver in mice.

Ann Arbor — Researchers at the University of Michigan’s Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice.

The findings from the lab of Alan Saltiel, the Mary Sue Coleman director of the Life Sciences Institute, are published online in the journal Nature Medicine.

“One of the reasons that diets are so ineffective in producing weight loss for some people is that their bodies adjust to the reduced calories by also reducing their metabolism, so that they are ‘defending’ their body weight,” Saltiel said. “Amlexanox seems to tweak the metabolic response to excessive calorie storage in mice.”


Different formulations of amlexanox are currently prescribed to treat asthma in Japan and canker sores in the United States. Saltiel is teaming up with clinical-trial specialists at U-M to test whether amlexanox will be useful for treating obesity and diabetes in humans. He is also working with medicinal chemists at U-M to develop a new compound based on the drug that optimizes its formula.

The study appears to confirm and extend the notion that the genes IKKE and TBK1 play a crucial role for maintaining metabolic balance, a discovery published by the Saltiel lab in 2009 in the journal Cell.

“Amlexanox appears to work in mice by inhibiting two genes—IKKE and TBK1—that we think together act as a sort of brake on metabolism,” Saltiel said. “By releasing the brake, amlexanox seems to free the metabolic system to burn more, and possibly store less, energy.”

Using high-throughput chemical screening at LSI’s Center for Chemical Genomics to search for compounds that inhibit IKKE and TBK1, the researchers hit upon an approved off-patent drug: amlexanox. They then demonstrated that amlexanox had profound beneficial effects in both genetic and dietary-induced obese mice. The chemical lowered the weight of obese mice and reversed related metabolic problems such as diabetes and fatty liver.

“These studies tell us that, at least in mice, the IKKE/TBK1 pathway plays an important role in defending body weight by increasing storage and decreasing burning of calories, and that by inhibiting that pathway with a compound, we can increase metabolism and induce weight loss, reverse diabetes and reduce fatty liver,” Saltiel said.

The drug has been on the market in Japan for more than 25 years.

However, the researchers don’t yet know if humans respond with the same pathway, or if the discovery of amlexanox’s effectiveness in mice can lead to a compound that is safe and effective for treating obesity and diabetes in humans.

“We will be working hard on that,” Saltiel said.

Saltiel’s search for a drug targeting the IKKE/TBK1 pathway was supported by the Life Science Institute’s Innovation Partnership, which provides philanthropic funding and business mentorship to help move promising research toward commercialization.

The research was also supported by the National Institutes of Health, the Michigan Diabetes Research and Training Center, the Michigan Institute for Clinical and Health Research, and the Nathan Shock Center in the Basic Biology of Aging.

Additional authors were Shannon M. Reilly, Shian-Huey Chiang, Stuart J. Decker, Louise Chang, Martha J. Larsen, John R. Rubin, Nicole M. White and Irit Hochberg from the Life Sciences Institute; Maeran Uhm and Jonathan Mowers from the Life Sciences Institute and Departments of Internal Medicine and Molecular and Integrative Physiology at the University of Michigan; Michael Downes, Ruth Yu and Ronald M. Evans from the Salk Institute for Biological Sciences; Christopher Liddle from the Storr Liver Unit, Westmead Millennium Institute and University of Sydney, Australia; and Dayoung Oh, Pingping Li, and Jerrold M. Olefsky from the Department of Medicine, University of California, San Diego.

Saltiel is the Mary Sue Coleman director of the Life Sciences Institute, where his laboratory is located and all his research is conducted. He is also the John Jacob Abel Collegiate Professor in the Life Sciences and a professor of internal medicine and molecular and integrative physiology at University of Michigan Medical School.

Comments

Post a Comment

Popular posts from this blog

Chelyabinsk Meteor And 2012 DA14

Image
On February 15, 2013, an asteroid entered the Earth’s atmosphere over the southern Ural region of Russia and exploded. The event was witnessed by thousands of people and became the largest known airburst since the 1908 Tunguska event. The blast produced a light brighter than the Sun, and the shock wave was felt by people all over the area. The energy of the explosion was equivalent to 20-30 of the atomic bombs used at Hiroshima. The asteroid was not detected by the authorities before the airburst, and the event surprised many people. It wounded 1,500 and damaged over 7,000 buildings. The meteor was caught on tape by multiple sources, which shows a giant fireball in the sky - followed by an enormous explosion of light. It was reported that the meteor made the ground hot, and the city smelled like gunpowder after the explosion. The event was an extremely rare occurrence and the only time in history that a meteor has been known to cause human injury.
Read more

Charity Destroys Lives

Image
By its very definition, charity is selfless. Whether it’s dropping a few pennies in a collection box or shipping our old T-shirts off to Africa, a spot of charity is a quick and easy way to net some karma. At least it would be if it didn’t usually harm the very people we’re trying to help. Take our practice of sending old clothes to Africa. Objectively, it makes sense: People living on under a dollar a day probably don’t have much of a clothing budget, so why not redistribute the stuff we’re not using? In fact, it makes so much sense that millions of us pack and ship off our novelty Christmas jumpers every year - resulting in the complete collapse of the African textile industry. Think about it: If you flood a market with free goods, you’ll bankrupt the traders and manufacturers trying to sell them. And that’s exactly what’s happened here. Across the continent, whole communities have lost their livelihoods in exchange for your old Slayer T-shirts.
Read more

BIZARRE MEDIEVAL MEDICAL PRACTICES

Image
Medicine is one of the cornerstones of modern civilization - so much so that we take it for granted. It wasn’t always the case that you could just waltz into a doctor’s office to have them cure what ailed you. In medieval times, for example, things were a lot more dangerous, and a lot stranger. Boar Bile Enemas Enemas in medieval times were performed by devices called clysters. A clyster was a long metal tube with a cup on the end. The tube would be entered into the anus and a medicinal fluid poured into the cup. The fluid would then be introduced into the colon by a series of pumping actions. Although warm soapy water is used for enemas today, things were a little more earthy back then: one of the most common fluids finding its way into a clyster was a concoction of boar’s bile. Even kings were high up on the clyster. King Louis XIV of France is said to have had over 2,000 enemas during his reign - some even administered while he sat on his throne.
Read more